APOC2_CAVPO
ID APOC2_CAVPO Reviewed; 100 AA.
AC P27916;
DT 01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT 01-AUG-1992, sequence version 1.
DT 03-AUG-2022, entry version 105.
DE RecName: Full=Apolipoprotein C-II;
DE Short=Apo-CII;
DE Short=ApoC-II;
DE AltName: Full=Apolipoprotein C2;
DE Contains:
DE RecName: Full=Proapolipoprotein C-II;
DE Short=ProapoC-II;
DE Flags: Precursor;
GN Name=APOC2;
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Hystricomorpha; Caviidae;
OC Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX PubMed=1999402; DOI=10.1016/s0021-9258(20)64287-9;
RA Andersson Y., Thelander L., Bengtsson-Olivecrona G.;
RT "Demonstration of apolipoprotein CII in guinea pigs. Functional
RT characteristics, cDNA sequence, and tissue expression.";
RL J. Biol. Chem. 266:4074-4080(1991).
CC -!- FUNCTION: Component of chylomicrons, very low-density lipoproteins
CC (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins
CC (HDL) in plasma. Plays an important role in lipoprotein metabolism as
CC an activator of lipoprotein lipase. Both proapolipoprotein C-II and
CC apolipoprotein C-II can activate lipoprotein lipase.
CC {ECO:0000250|UniProtKB:P02655}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02655}.
CC -!- TISSUE SPECIFICITY: Liver. {ECO:0000269|PubMed:1999402}.
CC -!- PTM: Proapolipoprotein C-II is synthesized as a sialic acid containing
CC glycoprotein which is subsequently desialylated prior to its
CC proteolytic processing. {ECO:0000250|UniProtKB:P02655}.
CC -!- PTM: Proapolipoprotein C-II, the major form found in plasma undergoes
CC proteolytic cleavage of its N-terminal hexapeptide to generate
CC apolipoprotein C-II, which occurs as the minor form in plasma.
CC {ECO:0000250|UniProtKB:P02655}.
CC -!- SIMILARITY: Belongs to the apolipoprotein C2 family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; M59913; AAA37031.1; -; mRNA.
DR PIR; A38685; A38685.
DR RefSeq; NP_001166385.1; NM_001172914.2.
DR RefSeq; XP_013002235.1; XM_013146781.1.
DR AlphaFoldDB; P27916; -.
DR SMR; P27916; -.
DR STRING; 10141.ENSCPOP00000019331; -.
DR PRIDE; P27916; -.
DR Ensembl; ENSCPOT00000022988; ENSCPOP00000019331; ENSCPOG00000009302.
DR GeneID; 100135480; -.
DR KEGG; cpoc:100135480; -.
DR CTD; 344; -.
DR eggNOG; ENOG502SEJB; Eukaryota.
DR GeneTree; ENSGT00390000007913; -.
DR HOGENOM; CLU_180154_0_0_1; -.
DR InParanoid; P27916; -.
DR OMA; EVQGAHL; -.
DR OrthoDB; 1548460at2759; -.
DR TreeFam; TF338218; -.
DR Proteomes; UP000005447; Unassembled WGS sequence.
DR Bgee; ENSCPOG00000009302; Expressed in liver and 5 other tissues.
DR GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
DR GO; GO:0034363; C:intermediate-density lipoprotein particle; IEA:Ensembl.
DR GO; GO:0034362; C:low-density lipoprotein particle; IEA:UniProtKB-KW.
DR GO; GO:0034366; C:spherical high-density lipoprotein particle; IEA:Ensembl.
DR GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.
DR GO; GO:0055102; F:lipase inhibitor activity; IEA:Ensembl.
DR GO; GO:0008289; F:lipid binding; IEA:Ensembl.
DR GO; GO:0060230; F:lipoprotein lipase activator activity; IEA:Ensembl.
DR GO; GO:0016004; F:phospholipase activator activity; IEA:Ensembl.
DR GO; GO:0043274; F:phospholipase binding; IEA:Ensembl.
DR GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl.
DR GO; GO:0034382; P:chylomicron remnant clearance; IEA:Ensembl.
DR GO; GO:0034384; P:high-density lipoprotein particle clearance; IEA:Ensembl.
DR GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR GO; GO:0032375; P:negative regulation of cholesterol transport; IEA:Ensembl.
DR GO; GO:0045833; P:negative regulation of lipid metabolic process; IEA:Ensembl.
DR GO; GO:0048261; P:negative regulation of receptor-mediated endocytosis; IEA:Ensembl.
DR GO; GO:0010916; P:negative regulation of very-low-density lipoprotein particle clearance; IEA:Ensembl.
DR GO; GO:0033700; P:phospholipid efflux; IEA:Ensembl.
DR GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IEA:Ensembl.
DR GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IEA:Ensembl.
DR GO; GO:0010518; P:positive regulation of phospholipase activity; IEA:Ensembl.
DR GO; GO:0060697; P:positive regulation of phospholipid catabolic process; IEA:Ensembl.
DR GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IEA:Ensembl.
DR GO; GO:0070328; P:triglyceride homeostasis; IEA:Ensembl.
DR Gene3D; 1.10.1440.10; -; 1.
DR InterPro; IPR008019; Apo-CII.
DR InterPro; IPR023121; ApoC-II_dom_sf.
DR PANTHER; PTHR16566; PTHR16566; 1.
DR Pfam; PF05355; Apo-CII; 1.
PE 2: Evidence at transcript level;
KW Chylomicron; Glycoprotein; HDL; LDL; Lipid degradation; Lipid metabolism;
KW Lipid transport; Reference proteome; Secreted; Sialic acid; Signal;
KW Transport; VLDL.
FT SIGNAL 1..25
FT /evidence="ECO:0000255"
FT CHAIN 26..100
FT /note="Proapolipoprotein C-II"
FT /id="PRO_0000002023"
FT CHAIN 32..100
FT /note="Apolipoprotein C-II"
FT /evidence="ECO:0000250|UniProtKB:P02655"
FT /id="PRO_0000430837"
FT REGION 65..73
FT /note="Lipid binding"
FT /evidence="ECO:0000250|UniProtKB:P02655"
FT REGION 77..100
FT /note="Lipoprotein lipase cofactor"
FT /evidence="ECO:0000250|UniProtKB:P02655"
SQ SEQUENCE 100 AA; 10985 MW; BBCF8DB52FC9E9BD CRC64;
MDARSLLLLW LLLPLLLLLG CEVQGAHLTQ QDEPTSPDLL ETLSTYWDSA KAAAQGLYNN
TYLPAVDETI RDIYSKGSAA ISTYTGILTD QILTMLQGKQ
